Literature DB >> 17962810

Sporadic childhood hepatoblastomas show activation of beta-catenin, mismatch repair defects and p53 mutations.

Maria C Curia1, Michele Zuckermann, Laura De Lellis, Teresa Catalano, Rossano Lattanzio, Gitana Aceto, Serena Veschi, Alessandro Cama, Jean-Bernard Otte, Mauro Piantelli, Renato Mariani-Costantini, Francesco Cetta, Pasquale Battista.   

Abstract

Hepatoblastoma, a rare embryonic tumor that may arise sporadically or in the context of hereditary syndromes (familial adenomatous polyposis and Beckwith-Wiedemann's) is the most frequent liver cancer of childhood. Deregulation of the APC/beta-catenin pathway occurs in a consistent fraction of hepatoblastomas, with mutations in the APC and beta-catenin genes implicated in familial adenomatous polyposis-associated and sporadic hepatoblastomas, respectively. Alterations in other cancer-related molecular pathways have not been reported. We investigated a series of 21 sporadic paraffin-embedded hepatoblastoma cases for mutations in the p53 (exons 5-8) and beta-catenin (exon 3) genes, loss of heterozygosity at APC, microsatellite instability and immunohistochemical expression of beta-catenin and of the two main mismatch repair proteins, MLH1 and MSH2. No loss of heterozygosity at APC was detected. We found mutations in beta-catenin and p53 in 4/21 (19%) and 5/21 (24%) cases respectively, beta-catenin protein accumulation in 14/21 cases (67%), microsatellite instability in 17/21 cases (81%), of which eight resulted positive for high-level of microsatellite instability (in four cases associated with loss of MLH1/MSH2 immunostaining). No correlations between involved molecular pathway(s) and hepatoblastoma histotype(s) emerged. This study confirms that beta-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer. Sporadic hepatoblastoma appears to be molecularly and phenotypically heterogeneous and may reflect different pathways of liver carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962810     DOI: 10.1038/modpathol.3800977

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  Calpain induces N-terminal truncation of β-catenin in normal murine liver development: diagnostic implications in hepatoblastomas.

Authors:  Abigale Lade; Sarangarajan Ranganathan; Jianhua Luo; Satdarshan P S Monga
Journal:  J Biol Chem       Date:  2012-05-21       Impact factor: 5.157

3.  Gene expression profiling of human hepatoblastoma using archived formalin-fixed and paraffin-embedded tissues.

Authors:  Eun Shin; Kyoung-Bun Lee; Soo-Young Park; Soo-Hee Kim; Han-Suk Ryu; Young-Nyun Park; Eunsil Yu; Ja-June Jang
Journal:  Virchows Arch       Date:  2011-03-03       Impact factor: 4.064

Review 4.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

5.  Hepatoblastoma in two siblings and familial adenomatous polyposis: causal nexus or coincidence?

Authors:  Christina Evers; Harald Gaspar; Matthias Kloor; Gergana Bozukova; Martina Kadmon; Monika Keller; Christian Sutter; Ute Moog
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

6.  Pharmacological inhibition of beta-catenin in hepatoblastoma cells.

Authors:  V Ellerkamp; J Lieber; C Nagel; J Wenz; S W Warmann; J Fuchs; S Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-12-25       Impact factor: 1.827

7.  Unifying cancer genetics.

Authors:  Sharon E Plon
Journal:  Genet Med       Date:  2011-03       Impact factor: 8.822

8.  HGF/c-Met related activation of β-catenin in hepatoblastoma.

Authors:  Rachel Purcell; Margaret Childs; Rudolf Maibach; Carina Miles; Clinton Turner; Arthur Zimmermann; Michael Sullivan
Journal:  J Exp Clin Cancer Res       Date:  2011-10-12

9.  Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients.

Authors:  Talita Ferreira Marques Aguiar; Maria Prates Rivas; Silvia Costa; Mariana Maschietto; Tatiane Rodrigues; Juliana Sobral de Barros; Anne Caroline Barbosa; Renan Valieris; Gustavo R Fernandes; Debora R Bertola; Monica Cypriano; Silvia Regina Caminada de Toledo; Angela Major; Israel Tojal; Maria Lúcia de Pinho Apezzato; Dirce Maria Carraro; Carla Rosenberg; Cecilia Maria Lima da Costa; Isabela W Cunha; Stephen Frederick Sarabia; Dolores-López Terrada; Ana Cristina Victorino Krepischi
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

10.  PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.

Authors:  Laura L Stafman; Adele P Williams; Raoud Marayati; Jamie M Aye; Jerry E Stewart; Elizabeth Mroczek-Musulman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2019-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.